330 related articles for article (PubMed ID: 30971397)
21. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
[TBL] [Abstract][Full Text] [Related]
22. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.
Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ
Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393
[TBL] [Abstract][Full Text] [Related]
23. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
Shah HH; Fishbane S
Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
[TBL] [Abstract][Full Text] [Related]
24. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
Aapro M; Moebus V; Nitz U; O'Shaughnessy J; Pronzato P; Untch M; Tomita D; Bohac C; Leyland-Jones B
Ann Oncol; 2015 Apr; 26(4):688-695. PubMed ID: 25542926
[TBL] [Abstract][Full Text] [Related]
26. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
[TBL] [Abstract][Full Text] [Related]
27. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z; DeSantis ER
Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
[TBL] [Abstract][Full Text] [Related]
28. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
29. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
Rizzo JD; Lichtin AE; Woolf SH; Seidenfeld J; Bennett CL; Cella D; Djulbegovic B; Goode MJ; Jakubowski AA; Lee SJ; Miller CB; Rarick MU; Regan DH; Browman GP; Gordon MS; ;
Blood; 2002 Oct; 100(7):2303-20. PubMed ID: 12239138
[TBL] [Abstract][Full Text] [Related]
30. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
32. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
33. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
34. In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
Ingrasciotta Y; Belleudi V; Trotta F; Addis A; Fontana A; Chinellato A; Ientile V; Tari DU; Roberto G; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Rossi M; Trifirò G;
BioDrugs; 2020 Feb; 34(1):55-64. PubMed ID: 31595485
[TBL] [Abstract][Full Text] [Related]
35. Pharmacovigilance in practice: erythropoiesis-stimulating agents.
Hedenus M; Ludwig H; Henry DH; Gasal E
Cancer Med; 2014 Oct; 3(5):1416-29. PubMed ID: 24890561
[TBL] [Abstract][Full Text] [Related]
36. Anemia management in oncology and hematology.
Spivak JL; Gascón P; Ludwig H
Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
[TBL] [Abstract][Full Text] [Related]
37. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
Bohlius J; Tonia T; Schwarzer G
Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
[TBL] [Abstract][Full Text] [Related]
38. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
39. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
40. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
